17. Capacity and barriers in diagnosis and treatment of advanced HIV disease and opportunistic infections of ARV clinics in Vietnam
Main Article Content
Abstract
In 2021, Vietnam’s Ministry of Health adopted the World Health Organization’s Package of Care For People With Advanced HIV Disease into the National Guidelines of HIV management to further reduce the burden of HIV-induced mortality. Our mixed research aimed to evaluate the feasibility of applying the Package in 41 clinical units in Vietnam. Results showed there were only 3/41 (7.3%) facilities conducted CD4 test or viral load locally. There were also limitations in diagnosis of opportunistic infections as 34/41 (82.9%) and 33/41 (80.5%) facilities were not able to identify cryptococcus and Talaromyces marneffei, respectively. Only 1 facility performed the serum CrAg test, and no facility could test CrAg in cerebrospinal liquid. The qualitative assessment reflected a shortage of human resources, equipment and biological materials for medical tests, and frequent interruption of medication supplies to treatment facilities.
Article Details
Keywords
Advanced HIV disease, Opportunistic infections, Test, Diagnosis
References
2. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568-2577. doi: 10.1001/jama.286.20.2568.
3. Low A, Gavriilidis G, Larke N, et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: A systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(12):1595-1603. doi: 10.1093/cid/ciw125.
4. World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy, July 2017. World Health Organization; 2017. Accessed September 19, 2022. https://apps.who.int/iris/handle/10665/255884.
5. World Health Organization. Consolidated Guidelines on Person-Centred HIV Strategic Information: Strengthening Routine Data for Impact. World Health Organization; 2022. Accessed September 19, 2022. https://apps.who.int/iris/handle/10665/360948.
6. Dat VQ, Lyss S, Dung NTH, et al. Prevalence of advanced HIV disease, cryptococcal antigenemia, and suboptimal clinical outcomes among those enrolled in care in Vietnam. J Acquir Immune Defic Syndr 1999. 2021;88(5):487-496. doi: 10.1097/QAI.0000000000002786.
7. Bộ Y tế. Hướng dẫn điều trị và chăm sóc HIV/AIDS. 2021. https://vaac.gov.vn/van-ban/59862021.html.
8. Nguyễn Văn Huy, Vũ Toàn Thịnh, Phan Thị Thu Hương. Nhân lực của hệ thống phòng chống HIV/AIDS địa phương năm 2013 - Kết quả từ một nghiên cứu định tính. Tạp chí Y học dự phòng. 2014;7(24):59.
9. Hứa Thanh Thủy, Trần Quỳnh Anh, Nguyễn Thanh Hương. Thực trạng và nhu cầu nhân lực y tế phòng, chống HIV/AIDS tại 14 tỉnh Dự án Nâng cao năng lực phòng chống HIV/AIDS khu vực tiểu vùng Mê Kông mở rộng năm 2014. Tạp chí Y học dự phòng. 2017;5(27):211.
10. Steingart KR, Ramsay A, Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther. 2007;5(3):327-331. doi: 10.1586/14787210.5.3.327.
11. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015. doi: 10.1056/NEJMoa0907847.
12. World Health Organization. Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for the Diagnosis of Active Tuberculosis in People Living with HIV: Policy Update 2019. World Health Organization; 2019. Accessed September 19, 2022. https://apps.who.int/iris/handle/10665/329479.
13. Suwanpimolkul G, Kawkitinarong K, Manosuthi W, et al. Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: Prospective TB cohort from the Thailand Big City TB Research Network. Int J Infect Dis. 2017;59:96-102. doi: 10.1016/j.ijid.2017.04.017.
14. Hevey MA, George IA, Rauseo AM, Larson L, Powderly W, Spec A. Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV. J Clin Microbiol. 2020;58(11):e01563-20. doi: 10.1128/JCM.01563-20.
15. Mpoza E, Mukaremera L, Kundura DA, et al. Evaluation of a point-of-care immunoassay test kit “StrongStep” for cryptococcal antigen detection. PloS One. 2018;13(1):e0190652. doi: 10.1371/journal.pone.0190652.
16. Thu N. Asymptomatic Talaromyces (Penicillium) marneffei antigenemia and mortality in advanced HIV disease. in The annual Conference on Retroviruses and Opportunistic Infections. Published online 2019.